Whilst AOD-9604 was not successful in human trials aimed at obesity, the Company believes there is sufficient efficacy data to enable a potential food, drink or dietary supplement product to be successfully marketed in the US.'' ASADA investigators are expected to hand down their report in the next fortnight.
Perfect B is currently evaluating AOD 9604 internally and does not yet offer it to patients
By inhibiting NNMT, the body maintains higher NAD levels, which in turn activate SIRT1, a longevity-associated gene, which may improve mitochondrial activity, fat oxidation, insulin sensitivity, and by overall energy balance
All communication with your prescribing physician, the MWLCOA admin team, and the pharmacy will take place securely through your HIPAA-compliant patient portal
ISBN 978-0-8493-5542-4